Dr. Agarwals Health Care Ltd (AGARWALEYE) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company achieved a landmark milestone by crossing 2,000 crores in annual revenue for the first time in its history, driven by the trust of over 30 lakh patients and a dedicated team of over 1,000 doctors.
- Q4 FY26 was reported as a strong and well-rounded quarter, delivering the highest quarterly EBITDA margin of the year at 30.2%, despite the costs associated with opening 19 new facilities during the period.
- The company demonstrated robust expansion through its Greenfield strategy, commissioning 19 new facilities in Q4 and a total of 148 since FY23, significantly strengthening its network presence across 14 states and 155 cities.
- Patient footfall saw a significant 25% increase, with daily walk-ins growing from approximately 8,000 to nearly 10,000, underscoring growing brand trust and successful market penetration.
- The company continues to focus on clinical excellence and advanced procedures, with high-end robotic cataract surgeries growing by a robust 87% YoY for the full year, indicating a successful push towards premiumization.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.